Váróczy László, Gergely Lajos, Miltényi Zsófia, Aleksza Magdolna, Illés Arpád
Division of Immuno-Hematology, Third Department of Medicine, Medical and Health Science Centre, University of Debrecen, P.O. Box 3, H-4004 Debrecen, Hungary.
Immunol Lett. 2005 Feb 15;97(1):155-7. doi: 10.1016/j.imlet.2004.10.005.
The immune system has several mechanisms to fight against developing malignant cell clones in the host, one of them is the activated T-cell response. Both CD4+ helper and CD8+ cytotoxic T-cells bear HLA-DR molecules as important surface activation markers. Our aim was to determine, how the ratio of activated T cells change in the peripheral blood of non-Hodgkin's lymphoma (NHL) patients during the periods of polychemotherapy. Using the methods of immunofluorescence staining and flow cytometry, we found the ratio of CD3+/HLA-DR+ cells significantly higher in NHL patients before treatment compared to healthy controls (10.63% versus 2.97%, P<0.001). During the period of polychemotherapy, this ratio began to increase significantly (10.63% versus 16.94%, P=0.006). After treatment, the ratio of activated T cells decreased, however, we detected significantly higher rate of CD3+/HLA-DR+ lymphocytes in patients who relapsed within 1 year than in those who stayed in remission (9.55% versus 20.62%, P<0.001). We suppose that investigation of CD3+/HLA-DR+ activated T cells might be a promising method to determine the prognostics of lymphoma patients.
免疫系统有多种机制来对抗宿主体内正在形成的恶性细胞克隆，其中之一是活化的T细胞反应。CD4+辅助性T细胞和CD8+细胞毒性T细胞都带有HLA-DR分子作为重要的表面活化标志物。我们的目的是确定在多药化疗期间非霍奇金淋巴瘤（NHL）患者外周血中活化T细胞的比例如何变化。使用免疫荧光染色和流式细胞术方法，我们发现与健康对照相比，NHL患者治疗前CD3+/HLA-DR+细胞的比例显著更高（10.63%对2.97%，P<0.001）。在多药化疗期间，这一比例开始显著增加（10.63%对16.94%，P=0.006）。治疗后，活化T细胞的比例下降，然而，我们检测到在1年内复发的患者中CD3+/HLA-DR+淋巴细胞的比例显著高于那些处于缓解期的患者（9.55%对20.62%，P<0.001）。我们推测，对CD3+/HLA-DR+活化T细胞的研究可能是一种确定淋巴瘤患者预后的有前景的方法。
